Recent progress in TGF-β inhibitors for cancer therapy.
暂无分享,去创建一个
T. Hu | Pei-Feng Liu | Chun-Lin Chen | Chih-Ling Chung | Jih-Jung Chen | Cheng-Yi Huang | Tsung‐Hui Hu
[1] Liangjing Lu,et al. Understanding Fibrosis in Systemic Sclerosis: Novel and Emerging Treatment Approaches , 2020, Current Rheumatology Reports.
[2] S. Jimenez,et al. Increased expression of the transforming growth factor β-inducible gene HIC-5 in systemic sclerosis skin and fibroblasts: a novel antifibrotic therapeutic target. , 2020, Rheumatology.
[3] Tingting Li,et al. Matrix stiffness modulates ILK-mediated YAP activation to control the drug resistance of breast cancer cells. , 2019, Biochimica et biophysica acta. Molecular basis of disease.
[4] Zhi-Heng He,et al. Cancer-associated fibroblast regulate proliferation and migration of prostate cancer cells through TGF-β signaling pathway. , 2019, Life sciences.
[5] T. Hu,et al. Roles of Myosin-Mediated Membrane Trafficking in TGF-β Signaling , 2019, International journal of molecular sciences.
[6] Hong Zhang,et al. Transforming growth factor β signaling pathway: A promising therapeutic target for cancer , 2019, Journal of cellular physiology.
[7] Eduard Batlle,et al. Transforming Growth Factor-β Signaling in Immunity and Cancer. , 2019, Immunity.
[8] A. Ooshima,et al. Phosphorylation status at Smad3 linker region modulates transforming growth factor‐β‐induced epithelial‐mesenchymal transition and cancer progression , 2019, Cancer science.
[9] Seong-Jin Kim,et al. Preclinical Studies and a Phase I Trial of the TGF-β Receptor Inhibitor, Vactosertib (TEW-7197), in Combination with Pomalidomide in Patients with Multiple Myeloma Refractory to Bortezomib or Lenalidomide , 2018, Blood.
[10] M. Shiao,et al. Sorafenib suppresses TGF‐&bgr; responses by inducing caveolae/lipid raft‐mediated internalization/degradation of cell‐surface type II TGF‐&bgr; receptors: Implications in development of effective adjunctive therapy for hepatocellular carcinoma , 2018, Biochemical pharmacology.
[11] Y. Kuo,et al. Polyprenylated polycyclic acylphloroglucinol: Angiogenesis inhibitor from Garcinia multiflora. , 2018, Bioorganic & medicinal chemistry letters.
[12] Deng-Chyang Wu,et al. Pentachloropseudilin Inhibits Transforming Growth Factor‐β (TGF‐β) Activity by Accelerating Cell‐Surface Type II TGF‐β Receptor Turnover in Target Cells , 2018, Chembiochem : a European journal of chemical biology.
[13] M. Shiao,et al. Pentabromopseudilin: a myosin V inhibitor suppresses TGF-β activity by recruiting the type II TGF-β receptor to lysosomal degradation , 2018, Journal of enzyme inhibition and medicinal chemistry.
[14] H. Thieme,et al. First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery , 2017, PloS one.
[15] Seong-Jin Kim,et al. Abstract 2647: TGF-β type I receptor inhibitor (TEW-7197) diminishes myeloma progression by multiple immunomodulatory mechanisms in combination with ixazomib , 2017 .
[16] Jia-Ming Chang,et al. 7‐Dehydrocholesterol (7‐DHC), But Not Cholesterol, Causes Suppression of Canonical TGF‐β Signaling and Is Likely Involved in the Development of Atherosclerotic Cardiovascular Disease (ASCVD) , 2017, Journal of cellular biochemistry.
[17] Ajay K. Singh,et al. A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis , 2017, Kidney international reports.
[18] Ming-Wei Lin,et al. Cholest-4-en-3-one attenuates TGF-β responsiveness by inducing TGF-β receptors degradation in Mv1Lu cells and colorectal adenocarcinoma cells , 2017, Journal of receptor and signal transduction research.
[19] Pei-Yu Chen,et al. Pentabromophenol suppresses TGF-β signaling by accelerating degradation of type II TGF-β receptors via caveolae-mediated endocytosis , 2017, Scientific Reports.
[20] Z. Wen,et al. A Small Dibromotyrosine Derivative Purified From Pseudoceratina Sp. Suppresses TGF‐β Responsiveness by Inhibiting TGF‐β Type I Receptor Serine/Threonine Kinase Activity , 2016, Journal of cellular biochemistry.
[21] N. Senzer,et al. Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer. , 2016, Gynecologic oncology.
[22] A. Brandes,et al. A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. , 2016, Neuro-oncology.
[23] C. Hill. Transcriptional Control by the SMADs. , 2016, Cold Spring Harbor perspectives in biology.
[24] F. Huang,et al. DMSO Enhances TGF‐β Activity by Recruiting the Type II TGF‐β Receptor From Intracellular Vesicles to the Plasma Membrane , 2016, Journal of cellular biochemistry.
[25] F. Huang,et al. Ethanol Enhances TGF‐β Activity by Recruiting TGF‐β Receptors From Intracellular Vesicles/Lipid Rafts/Caveolae to Non‐Lipid Raft Microdomains , 2016, Journal of cellular biochemistry.
[26] C. L. Chen,et al. Betulinic acid enhances TGF-β signaling by altering TGF-β receptors partitioning between lipid-raft/caveolae and non-caveolae membrane microdomains in mink lung epithelial cells , 2016, Journal of Biomedical Science.
[27] Katsunori Yoshida,et al. Reversible Human TGF-β Signal Shifting between Tumor Suppression and Fibro-Carcinogenesis: Implications of Smad Phospho-Isoforms for Hepatic Epithelial-Mesenchymal Transitions , 2016, Journal of clinical medicine.
[28] B. Hontanilla,et al. Effect of P144® (Anti-TGF-β) in an “In Vivo” Human Hypertrophic Scar Model in Nude Mice , 2015, PloS one.
[29] G. Giaccone,et al. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. , 2015, European journal of cancer.
[30] L. Desai,et al. Reciprocal regulation of TGF-β and reactive oxygen species: A perverse cycle for fibrosis , 2015, Redox biology.
[31] Ming-Wei Lin,et al. Euphol from Euphorbia tirucalli Negatively Modulates TGF-β Responsiveness via TGF-β Receptor Segregation inside Membrane Rafts , 2015, PloS one.
[32] S. Estrem,et al. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway , 2015, Drug design, development and therapy.
[33] P. Papageorgis. TGFβ Signaling in Tumor Initiation, Epithelial-to-Mesenchymal Transition, and Metastasis , 2015, Journal of oncology.
[34] N. Senzer,et al. Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.
[35] Jianlin Ren,et al. Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression , 2015, BMC Cancer.
[36] J. Berzofsky,et al. Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008) , 2015, Cancer Immunology, Immunotherapy.
[37] M. Farmen,et al. A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancer , 2014, International journal of oncology.
[38] Jeong-Seok Nam,et al. EW-7197, a Novel ALK-5 Kinase Inhibitor, Potently Inhibits Breast to Lung Metastasis , 2014, Molecular Cancer Therapeutics.
[39] J. Berzofsky,et al. Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma , 2014, PloS one.
[40] S. Dooley,et al. Comparative Analysis of TGF-β/Smad Signaling Dependent Cytostasis in Human Hepatocellular Carcinoma Cell Lines , 2013, PloS one.
[41] A. Paradiso,et al. Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II , 2013, PloS one.
[42] G. Giannelli,et al. Randomized dose comparison phase II study of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 monohydrate (LY) in patients with advanced hepatocellular carcinoma (HCC). , 2013 .
[43] Y. Koh,et al. Combined Treatment with Erlotinib and a Transforming Growth Factor-&bgr; Type I Receptor Inhibitor Effectively Suppresses the Enhanced Motility of Erlotinib-Resistant Non–Small-Cell Lung Cancer Cells , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[44] R. Akhurst,et al. Complexities of TGF-β Targeted Cancer Therapy , 2012, International journal of biological sciences.
[45] Martin A Nowak,et al. Dynamics of targeted cancer therapy. , 2012, Trends in molecular medicine.
[46] K. Schlingensiepen,et al. The antisense oligonucleotide trabedersen (AP 12009) for the targeted inhibition of TGF-β2. , 2011, Current pharmaceutical biotechnology.
[47] S. Dooley,et al. TGF-β in progression of liver disease , 2011, Cell and Tissue Research.
[48] Ute Wirkner,et al. Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761. , 2011, Neoplasia.
[49] K. Schlingensiepen,et al. Transforming growth factor‐beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer , 2011, Cancer science.
[50] B. Hann,et al. Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TβRI/II kinase inhibition with LY2109761. , 2011, Cancer research.
[51] G. Remuzzi,et al. A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis , 2011, Kidney international.
[52] N. Senzer,et al. Phase I Trial of TGF-β2 Antisense GM-CSF Gene-Modified Autologous Tumor Cell (TAG) Vaccine , 2011, Clinical Cancer Research.
[53] C. Gialeli,et al. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting , 2011, The FEBS journal.
[54] M. Zaaroor,et al. Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study , 2010, Neuro-oncology.
[55] K. Hahm,et al. Connection between inflammation and carcinogenesis in gastrointestinal tract: focus on TGF-beta signaling. , 2010, World journal of gastroenterology.
[56] S. Demaria,et al. Abstract 1395: Inhibition of transforming growth factor β (TGFβ) increases the therapeutic benefit of radiotherapy in a murine mammary tumor model , 2010 .
[57] Mikala Egeblad,et al. Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling , 2009, Cell.
[58] J. Soria,et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] S. Thorgeirsson,et al. Transforming growth factor‐β gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer , 2008, Hepatology.
[60] J. Berzofsky,et al. An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments. , 2008, Cancer research.
[61] V. Tsutsumi,et al. Resveratrol prevents fibrosis, NF‐κB activation and TGF‐β increases induced by chronic CCl4 treatment in rats , 2008 .
[62] K. Iles,et al. Glutathione suppresses TGF-beta-induced PAI-1 expression by inhibiting p38 and JNK MAPK and the binding of AP-1, SP-1, and Smad to the PAI-1 promoter. , 2007, American journal of physiology. Lung cellular and molecular physiology.
[63] B. Willis,et al. TGF-β-induced EMT: mechanisms and implications for fibrotic lung disease , 2007 .
[64] J. Pichler,et al. Inhibition of TGF-β2 with AP 12009 in Recurrent Malignant Gliomas: From Preclinical to Phase I/II Studies , 2007 .
[65] K. Miyazono,et al. Ki26894, a novel transforming growth factor‐β type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line , 2007, Cancer science.
[66] L. Wakefield,et al. Development of oncolytic adenovirus armed with a fusion of soluble transforming growth factor-beta receptor II and human immunoglobulin Fc for breast cancer therapy. , 2006, Human gene therapy.
[67] N. Senzer,et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] R. Flavell,et al. Transforming Growth Factor-β Controls Development, Homeostasis, and Tolerance of T Cells by Regulatory T Cell-Dependent and -Independent Mechanisms , 2006 .
[69] F. Hoffmann,et al. Inhibition of transforming growth factor-beta1-induced signaling and epithelial-to-mesenchymal transition by the Smad-binding peptide aptamer Trx-SARA. , 2006, Molecular biology of the cell.
[70] Ralph Weissleder,et al. Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation. , 2006, Immunity.
[71] J. Huang,et al. TGF‐β control of cell proliferation , 2005 .
[72] Jesús Prieto,et al. Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis. , 2005, The Journal of investigative dermatology.
[73] F. Hoffmann,et al. Selective inhibition of TGF-β responsive genes by Smad-interacting peptide aptamers from FoxH1, Lef1 and CBP , 2005, Oncogene.
[74] Jonathan M. Yingling,et al. Development of TGF-β signalling inhibitors for cancer therapy , 2004, Nature Reviews Drug Discovery.
[75] L. Pelkmans,et al. Not just a sink: endosomes in control of signal transduction. , 2004, Current opinion in cell biology.
[76] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[77] D. Bigner,et al. SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. , 2004, Molecular cancer therapeutics.
[78] A. Roberts,et al. SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7. , 2004, Molecular pharmacology.
[79] P. Bates,et al. Recognition of Phosphorylated-Smad2-Containing Complexes by a Novel Smad Interaction Motif , 2004, Molecular and Cellular Biology.
[80] Ying E. Zhang,et al. Smad-dependent and Smad-independent pathways in TGF-β family signalling , 2003, Nature.
[81] J. Massagué,et al. Mechanisms of TGF-β Signaling from Cell Membrane to the Nucleus , 2003, Cell.
[82] P. Ko Ferrigno,et al. Peptide aptamers: tools for biology and drug discovery. , 2003, Briefings in functional genomics & proteomics.
[83] C. Arteaga,et al. Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases , 2002 .
[84] D. Rockey,et al. Dose‐dependent inhibition of hepatic fibrosis in mice by a TGF‐β soluble receptor: Implications for antifibrotic therapy , 2002, Hepatology.
[85] S. Dooley,et al. Roles of TGF-beta in hepatic fibrosis. , 2002, Frontiers in bioscience : a journal and virtual library.
[86] R. Derynck,et al. TGF-β signaling in cancer – a double-edged sword , 2001 .
[87] Michael Platten,et al. Glioma Cell Invasion: Regulation of Metalloproteinase Activity by TGF-β , 2001, Journal of Neuro-Oncology.
[88] J. Massagué,et al. TGFβ Signaling in Growth Control, Cancer, and Heritable Disorders , 2000, Cell.
[89] Ester Piek,et al. Role of Transforming Growth Factor-β Signaling in Cancer , 2000 .
[90] M. Dembo,et al. Cell movement is guided by the rigidity of the substrate. , 2000, Biophysical journal.
[91] J. Massagué,et al. Transcriptional control by the TGF‐β/Smad signaling system , 2000 .
[92] B. Janji,et al. Autocrine TGF‐β‐regulated expression of adhesion receptors and integrin‐linked kinase in HT‐144 melanoma cells correlates with their metastatic phenotype , 1999, International journal of cancer.
[93] A. Churg,et al. Mechanisms in the pathogenesis of asbestosis and silicosis. , 1998, American journal of respiratory and critical care medicine.
[94] Xiao-Fan Wang,et al. Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[95] R. Leduc,et al. Processing of Transforming Growth Factor 1 Precursor by Human Furin Convertase (*) , 1995, The Journal of Biological Chemistry.
[96] Gregory J. Hannon,et al. pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest , 1994, Nature.
[97] Mahlon D. Johnson,et al. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. , 1993, The Journal of clinical investigation.
[98] J. Massagué,et al. Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-β receptor system , 1991, Cell.
[99] F. Pouliot,et al. TGFβ Signaling in the Tumor Microenvironment. , 2021, Advances in experimental medicine and biology.
[100] D. Rao,et al. Three-year Follow up of GMCSF/bi-shRNAfurin DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.
[101] S. Bhattacharyya,et al. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities , 2012, Nature Reviews Rheumatology.
[102] D. Rao,et al. Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.
[103] R. Liu,et al. Oxidative stress and glutathione in TGF-beta-mediated fibrogenesis. , 2010, Free radical biology & medicine.
[104] Ye-Guang Chen. Endocytic regulation of TGF-β signaling , 2009, Cell Research.
[105] J. Mora,et al. High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. , 2007, Cancer cell.
[106] B. Olson,et al. Inhibition of Transforming Growth Factor (TGF)- 1–Induced Extracellular Matrix with a Novel Inhibitor of the TGF- Type I Receptor Kinase Activity: SB-431542 , 2002 .
[107] D. Kingsley,et al. The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms. , 1994, Genes & development.
[108] J. Krstić,et al. Review Article Transforming Growth Factor-beta and Matrix Metalloproteinases: Functional Interactions in Tumor Stroma-infiltrating Myeloid Cells , 2022 .